<DOC>
	<DOCNO>NCT00147199</DOCNO>
	<brief_summary>This double-blind placebo-controlled clinical investigation efficacy tolerability inhale treprostinil patient severe pulmonary arterial hypertension . The primary outcome change 6-minute walk distance baseline week 12 .</brief_summary>
	<brief_title>Clinical Investigation Into Inhaled Treprostinil Sodium Patients With Severe Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>Patients stable dose 125 mg twice daily ( bid ) bosentan stable dose sildenafil least three month prior study start randomize either treprostinil inhalation solution match placebo . Administration study medication perform inhalation OPTINEB™ ultrasonic nebulizer . The propose dose regimen four time daily—upon awaken , midday , even ( dinner time ) bedtime . After patient complete twelve-week study period , give option enrol open-label extension study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Clinically stable , pulmonary arterial hypertension diagnose either idiopathic familial PAH , collagen vascular disease associate PAH , HIV PAH , PAH induce anorexigens , New York Heart Association ( NYHA ) Class III Class IV . Been stable dose 125 mg twice daily ( bid ) bosentan OR stable dose sildenafil least three month prior study start An unencouraged six minute walk test ( 6MWT ) 200 450 meter screen Cardiac catheterization within past 13 month consistent PAH , specifically mean pulmonary artery pressure ( PAPm ) ≥25 mmHg ( rest ) , pulmonary capillary wedge pressure ( PCWP ) ( leave ventricular end diastolic pressure ) ≤15 mmHg , pulmonary vascular resistance ( PVR ) &gt; 3 mmHg/L/min Within past 12 month , patient must chest radiograph consistent diagnosis PAH Willing able follow study procedure Considering pregnancy , pregnant and/or lactate PAH due condition note inclusion criterion . Have change discontinue PAH medication within last three month , include limited endothelin receptor antagonist ( ERA ) , calcium channel blocker ( CCB ) ( exception anticoagulant ) Have receive prostanoid within 30 day screen scheduled receive course study Have receive investigational medication within 30 day prior start study schedule receive another investigational drug course study Have know intolerance drug , especially treprostinil sodium prostanoids Have increase risk hemorrhage Have new type chronic therapy ( e.g. , different category vasodilator , diuretic ) PAH add within last month , except anticoagulant Have musculoskeletal disease disease would limit ambulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>